A

Aptevo Therapeutics

D
APVO
USD
0.0428
(16.5891%)
Market Closed
90,684.00
Volume
-12.52
EPS
-
Div Yield
-0.008950
P/E
4,043,105.14
Market Cap
Today
16.5891%
1 Week
11.407%
1 Month
83.863%
6 Months
-74.291%
12 Months
-96.938%
Year To Date
-96.301%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
A
ASND
-2.7
(-2.089%)
USD
A
ADMA
0.045
(0.2287%)
USD
A
APLT
0.09
(0.9326%)
USD
M
MRKR
0.51
(13.9344%)
USD
O
OCUL
-0.14
(-1.2809%)
USD
K
KURA
-0.075
(-0.4208%)
USD
L
LGND
18.7
(16.8408%)
USD
R
RIGL
0.38
(2.5216%)
USD

Title:
Aptevo Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Do you need help or have a question?
Contact Us